Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting | Statement: [ICH E2D, fullName, ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting]

Target entity: ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
Context triple: [ICH E2D, fullName, ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting]

• A. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• B. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• C. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• D. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• E. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
Target entity description: ICH E2D is an international regulatory guideline that standardizes how post-approval drug safety data are defined, managed, and rapidly reported to health authorities to ensure ongoing monitoring of medicinal product safety.

• A. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• B. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• C. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• D. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• E. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• F. None of above. chosen